

EURONET-SAMM project:

EUROpean NETwork
on Severe Acute Maternal Morbidity

Anne Chantry

Catherine Deneux-Tharaux

Inserm U1153, Epopé Team 

Plan


- Why should we study Severe Acute Maternal Morbidity (SAMM) ?
- SAMM in the last Europeristat report
- The EURONET-SAMM project

Why should we study SAMM?

- Although pregnancy and childbirth are generally healthy events
- They can be associated in some cases with maternal complications that can worsen and lead to maternal death.

- Risk factors of complications are increasing

- Evolution of maternal profiles
(↗age at pregnancy, ↗% obesity, severe medical history)
- Evolution of practices
(↗% induced labors, ↗% C-sections)



Necessity to monitor maternal health

Which indicator to monitor maternal health ?




Over 50 years, **maternal mortality** has been the traditional indicator of maternal health

But it has some limitations due to the scarcity of maternal deaths in high-resource countries:

- This prevents subgroups analyses by causes of death
- And implies long data collections with the risk of obsolete conclusions

➡ Need for a complementary indicator of severe complications



The SAMM indicator

- Main issue:
To date, there is still no internationally consensual definition of SAMM

Several previous propositions:

- Selection of diagnoses, procedures or organ failures, mainly for research focus

(Waterstone, BMJ 2001 -Zhang, BJOG 2005 –Geller, JCE 2004 –Mantel BJOG 98)

- WHO near-misses definition (2009): but this definition is controversial/ relevance for high-ressource countries?

(Say et al., Best Pract Obstet Gynecol 2009)

In the EURO-Peristat group

- The study of SAMM was an objective of the EURO-Peristat II Project

Objective 3

Point 2: Analyse data from selected countries on: generating maternal morbidity indicators from hospital discharge data and quality criteria

			Rates per 1000 women Blood transfusion							
Country/coverage	Source	Number of women	Eclampsia	ICU admission	3 units or more	5 units or more	Other amount	No units specified	Hysterectomy	Embolisation
Belgium										
Czech Republic	1	114 407	0.2	NA	NA	NA	NA	NA	0.3	NA
Denmark	1	62 203	0.5	NA	NA	NA	NA	NA	NA	NA
Germany	1	625 615	0.6	4.9	NA	NA	14.3	NA	1.0	0.0
Estonia	1	15 646	0.3	NA	NA	NA	NA	3.9	1.3	NA
Ireland										
Greece										
Spain										
ES: Catalonia										
ES: Valencia	6	37 236	0.3	NA	NA	NA	NA	8.1	0.5	NA
France	5	832 799	0.9	2.0	NA	NA	NA	6.5	0.7	1.4
Italy										
Cyprus										
Latvia	1	19 003	0.9	NA	NA	NA	NA	3.9	1.2	NA
Lithuania	1	30 568	0.4	NA	NA	NA	NA	NA	NA	NA
Luxembourg	1	6440	NA	3.7	NA	NA	NA	NA	NA	NA
Hungary										
Malta	1	3952	0.0	NA	0.6	0.1	0.7	0.0	0.3	NA
Netherlands										
Austria	4	78 989	0.2	NA	NA	NA	NA	NA	NA	NA
Poland	2	402 826	0.5	0.3	NA	NA	NA	12.3	0.3	0.3
Portugal	7	101 495	0.4	NA	NA	NA	NA	11.9	0.7	0.0
Romania	5	213 055	0.4	NA	NA	NA	NA	NA	NA	0.0
Slovenia	1	22 000	0.4	NA	NA	NA	NA	8.8	0.4	NA
Slovakia										
Finland	1,5	60 421	0.1	NA	NA	NA	NA	22.7	0.4	0.3
Sweden	1	113 488	0.1	NA	NA	NA	NA	NA	0.1	0.7
United Kingdom										
UK: Wales	6,7	32 649	NA	NA	NA	NA	NA	NA	0.0	0.2
UK: Scotland	2	56 529	0.1	NA	NA	NA	NA	NA	0.2	0.0
Iceland	1+4	4834	0.6	0.4	NA	NA	NA	NA	0.2	0.0
Norway	1	61 539	0.5	18.4	NA	NA	NA	18.0	0.3	0.1
Switzerland	3	78 784	0.6	2.3	NA	NA	NA	10.1	0.7	0.4

			Rates per 1000 women Blood transfusion							
Country/coverage	Source	Number of women	Eclampsia	ICU admission	3 units or more	5 units or more	Other amount	No units specified	Hysterectomy	Embolisation
Belgium										
Czech Republic	1	114 407	0.2						0.3	
Denmark	1	62 203	0.5							
Germany	1	625 615	0.6	4.9	NA	NA	14.3	NA	1.0	0.0
Estonia	1	15 646	0.3		NA	NA	NA	3.9	1.3	
Ireland										
Greece										
Spain										
ES: Catalonia										
ES: Valencia	6	37 236	0.3		NA	NA	NA	8.1	0.5	
France	5	832 799	0.9	2.0	NA	NA	NA	6.5	0.7	1.4
Italy										
Cyprus										
Latvia	1	19 003	0.9		NA	NA	NA	3.9	1.2	
Lithuania	1	30 568	0.4							
Luxembourg	1	6440	NA	3.7						
Hungary										
Malta	1	3952	0.0	NA	0.6	0.1	0.7	0.0	0.3	
Netherlands										
Austria	4	78 989	0.2							
Poland	2	402 826	0.5	0.3	NA	NA	NA	12.3	0.3	0.3
Portugal	7	101 495	0.4		NA	NA	NA	11.9	0.7	0.0
Romania	5	213 055	0.4							0.0
Slovenia	1	22 000	0.4		NA	NA	NA	8.8	0.4	
Slovakia										
Finland	1,5	60 421	0.1		NA	NA	NA	22.7	0.4	0.3
Sweden	1	113 488	0.1						0.1	0.7
United Kingdom										
UK: Wales	6,7	32 649							0.0	0.2
UK: Scotland	2	56 529	0.1						0.2	0.0
Iceland	1+4	4834	0.6	0.4					0.2	0.0
Norway	1	61 539	0.5	18.4	NA	NA	NA	18.0	0.3	0.1
Switzerland	3	78 784	0.6	2.3	NA	NA	NA	10.1	0.7	0.4



Lack of knowledge on SAMM in Europe

Lessons from EURO-Peristat II project

- Results are not contributive:
 - Over 50% of missing data
 - Only 5/32 member-states were able to provide all the criterion of SAMM
 - Wide variability for results between countries
 - 1 to 9 ratio for eclampsia / 1 to 14 for embolizations / 1 to 227 for transfusions

Nevertheless,

- All countries have permanent databases that could be used
(hospital discharge databases or perinatal registers, *etc...*)
- Variations may be due:
 - . To real differences
 - . To definition interpretations
 - . To an heterogeneous accuracy of the coding of events in databases



In the objective to improve the knoweldge on SAMM in Europe, we have built a research project

The EURONET-SAMM project

General objective: To assess the feasibility to study SAMM in Europe with a common definition from permanent databases



Step 1

- To build a network of partners
- To describe data sources and algorithms used to monitor SAMM in partners databases

Step 2

- To conceive a common algorithm for monitoring SAMM that characterize an homogeneous level of severity

Step 3

- To conduct a comparative pilot study of SAMM between partners once the common algorithm will be available



Network of 15 partners from 13 countries



Belgium



Denmark



France



Finland



Germany



Italy



Latvia



Netherlands



Poland



Portugal



Slovenia



Switzerland




United Kingdom (England/ Scotland/ Wales)



EURONET-SAMM methodology and calendar

Grants: 25 K€ from French Institut de REcherche en Santé Publique - IRESP

Duration: 1 year (from January 2016 to December 2016)





Thank you for your attention

